GanzeboomKS, MairuhuG, ReitsmaJB. Lifetime cumulative incidence of syncope in the general population: a study of 549 Dutch subjects aged 35-60 years. J Cardiovasc Electrophysiol2006; 17: 1172–6.
2.
SoteriadesES, EvansJC, LarsonMG. Incidence and prognosis of syncope. N Engl J Med2002; 347: 878–85.
3.
MoyaA, SuttonR, AmmiratiF. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J2009; 30: 2631–71. http://dx.doi.org/10.1093/eurheartj/ehp298
4.
RommeJJ, ReitsmaJB, Go-SchönIK. Prospective evaluation of non-pharmacological treatment in vasovagal syncope. Europace2010; 12: 567–73. http://dx.doi.org/10.1093/europace/eup414
5.
van DijkN, QuartieriF, BlancJJ. Effectiveness of physical counterpressure maneuvers in preventing vasovagal syncope: the Physical Counterpressure Manoeuvres Trial (PC-Trial). J Am Coll Cardiol2006; 48: 1652–7.
6.
RommeJJ, van DijkN, Go-SchönIK. Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial). Europace2011; 13: 1639–47. http://dx.doi.org/10.1093/europace/eur200
7.
SheldonR, ConnollyS, RoseS. Prevention of Syncope Trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope. Circulation2006; 113: 1164–70.
8.
Di GirolamoE, Di IorioC, SabatiniP. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol1999; 33: 1227–30.
9.
SalimMA, Di SessaTG. Effectiveness of fludrocortisone and salt in preventing syncope recurrence in children: a double blind, placebo-controlled, randomised trial. J Am Coll Cardiol2005: 45;484–8.
10.
SheldonR, RajSR, RoseMS. Fludrocortisone for the Prevention of Vasovagal Syncope: A Randomized, Placebo-Controlled Trial. J Am Coll Cardiol2016; 68: 1–9. http://dx.doi.org/10.1016/j.jacc.2016.04.030
11.
HussainRM, MacintoshSJ, LawsonJ. Fludrocortisone in the treatment of hypotensive disorders in the elderly. Heart1996; 76: 507–9.
12.
RajSR, FarisPD, McRaeM. Rationale for the prevention of syncope trial IV: assessment of midodrine. Clin Auton Res2012; 22: 275–80. http://dx.doi.org/10.1007/s10286-012-0167-5
